SCCO Southern delivers narrow Q4 2025 earnings beat shares edge down 1 percent on cautious investor sentiment OLB The OLB rises 23 percent after Q4 2025 earnings outpace consensus analyst EPS estimates Moderna Inc MRNA Counterparty Arbutus Biopharma Secures Regulatory Catalyst Amid Settled LNP Licensing Agreement ANVS Annovis Bio shares drop 387 after Q4 2025 wider loss misses analyst estimates by 114 GeneDx WGSWW Stock Extended Hours Weakens 20260427